BROMAZEPAM


Synonyms	Bromazepam Bromazepam civ Lectopam Lexatin Lexotan Lexotanil NSC-140669 RO 5-3350 RO-5-3350
Status
Molecule Category	Free-form
ATC	N05BA08
UNII	X015L14V0O
EPA CompTox	DTXSID40171081


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VMIYHDSEFNYJSL-UHFFFAOYSA-N
Smiles	O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1
InChI	InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C14H10BrN3O
Molecular Weight	316.16
AlogP	2.63
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	54.35
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	19.0

Bioactivity

Mechanism of Action	Action	Reference
GABA receptor alpha-2 subunit positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	PubMed PubMed PubMed PubMed PubMed


Protein: GABA receptor alpha-2 subunit Description: Gamma-aminobutyric acid receptor subunit alpha-2 Organism : Homo sapiens P47869 ENSG00000151834

Environmental Exposure

Environmental Exposure Map

Countries
Serbia

Cross References

Resources	Reference
ChEBI	31302
ChEMBL	CHEMBL277062
DrugBank	DB01558
DrugCentral	399
FDA SRS	X015L14V0O
Human Metabolome Database	HMDB0015511
PharmGKB	PA10035
PubChem	2441
SureChEMBL	SCHEMBL43933
ZINC	ZINC000000001051

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).